drugset / Trial / NCT06173596

A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

NCT06173596

Phase 1 Completed 60 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelOther

Summary

The primary objectives of this study are to determine the effect of multiple doses of itraconazole on the single dose PK of ALXN2080, to determine the effect of multiple doses of fluconazole on the single dose PK of ALXN2080 (optional), and to determine the effect of multiple doses of carbamazepine on the single dose PK of ALXN2080.

Timeline

Start
2024-01-10
Primary completion
2024-04-30
Completion
2024-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule Oral
Subject Fluconazole Small molecule Oral
Subject Itraconazole Small molecule Oral
Subject ZORACOPAN Small molecule Oral

Indications

No indication recorded.